Neurostimulation Devices Market (By Technology: Aneurysm coiling & embolization devices, Cerebral balloon angioplasty & Stenting systems, Support devices, Neurothrombectomy devices; By Disease Pathology: Ischemic Strokes, Cerebral Aneuryms, Carotid Artery Stenosis, Arteriovenous Malformations and Fistulas, Other Diseases; By Product; By Application; By End Users) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Neurostimulation Devices Market 

5.1. COVID-19 Landscape: Neurostimulation Devices Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Neurostimulation Devices Market, By Technology

8.1. Neurostimulation Devices Market, by January, 2022-2030

8.1.1. Aneurysm coiling & embolization devices

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Cerebral balloon angioplasty & Stenting systems

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Support devices

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Neurothrombectomy devices

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Neurostimulation Devices Market, By Disease Pathology

9.1. Neurostimulation Devices Market, by February, 2022-2030

9.1.1. Ischemic Strokes

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Cerebral Aneuryms

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Carotid Artery Stenosis

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Arteriovenous Malformations and Fistulas

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Other Diseases

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Neurostimulation Devices Market, By Product

10.1. Neurostimulation Devices Market, by March, 2022-2030

10.1.1. Spinal Cord Stimulator

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Deep Brain Stimulator

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Sacral Nerve Stimulator

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Vagus Nerve Stimulator

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Gastric Electric Stimulator

10.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Neurostimulation Devices Market, By Application

11.1. Neurostimulation Devices Market, by April, 2022-2030

11.1.1. Pain Management

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Epilepsy

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Essential Tremor

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Urinary and Fecal Incontinence

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Depression

11.1.5.1. Market Revenue and Forecast (2017-2030)

11.1.6. Dystonia

11.1.6.1. Market Revenue and Forecast (2017-2030)

11.1.7. Gastroparesis

11.1.7.1. Market Revenue and Forecast (2017-2030)

11.1.8. Parkinson’s Disease

11.1.8.1. Market Revenue and Forecast (2017-2030)

11.1.9. Others

11.1.9.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Neurostimulation Devices Market, By End Users

12.1. Neurostimulation Devices Market, by May, 2022-2030

12.1.1. Hospitals & Surgical Centers

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Ambulatory Care Centers

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Research Laboratories & Academic Institutes

12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Neurostimulation Devices Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by January (2017-2030)

13.1.2. Market Revenue and Forecast, by February (2017-2030)

13.1.3. Market Revenue and Forecast, by March (2017-2030)

13.1.4. Market Revenue and Forecast, by April (2017-2030)

13.1.5. Market Revenue and Forecast, by May (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by January (2017-2030)

13.1.6.2. Market Revenue and Forecast, by February (2017-2030)

13.1.6.3. Market Revenue and Forecast, by March (2017-2030)

13.1.6.4. Market Revenue and Forecast, by April (2017-2030)

13.1.7. Market Revenue and Forecast, by May (2017-2030) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by January (2017-2030)

13.1.8.2. Market Revenue and Forecast, by February (2017-2030)

13.1.8.3. Market Revenue and Forecast, by March (2017-2030)

13.1.8.4. Market Revenue and Forecast, by April (2017-2030)

13.1.8.5. Market Revenue and Forecast, by May (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by January (2017-2030)

13.2.2. Market Revenue and Forecast, by February (2017-2030)

13.2.3. Market Revenue and Forecast, by March (2017-2030)

13.2.4. Market Revenue and Forecast, by April (2017-2030) 

13.2.5. Market Revenue and Forecast, by May (2017-2030) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by January (2017-2030)

13.2.6.2. Market Revenue and Forecast, by February (2017-2030)

13.2.6.3. Market Revenue and Forecast, by March (2017-2030)

13.2.7. Market Revenue and Forecast, by April (2017-2030) 

13.2.8. Market Revenue and Forecast, by May (2017-2030) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by January (2017-2030)

13.2.9.2. Market Revenue and Forecast, by February (2017-2030)

13.2.9.3. Market Revenue and Forecast, by March (2017-2030)

13.2.10. Market Revenue and Forecast, by April (2017-2030)

13.2.11. Market Revenue and Forecast, by May (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by January (2017-2030)

13.2.12.2. Market Revenue and Forecast, by February (2017-2030)

13.2.12.3. Market Revenue and Forecast, by March (2017-2030)

13.2.12.4. Market Revenue and Forecast, by April (2017-2030)

13.2.13. Market Revenue and Forecast, by May (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by January (2017-2030)

13.2.14.2. Market Revenue and Forecast, by February (2017-2030)

13.2.14.3. Market Revenue and Forecast, by March (2017-2030)

13.2.14.4. Market Revenue and Forecast, by April (2017-2030)

13.2.15. Market Revenue and Forecast, by May (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by January (2017-2030)

13.3.2. Market Revenue and Forecast, by February (2017-2030)

13.3.3. Market Revenue and Forecast, by March (2017-2030)

13.3.4. Market Revenue and Forecast, by April (2017-2030)

13.3.5. Market Revenue and Forecast, by May (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by January (2017-2030)

13.3.6.2. Market Revenue and Forecast, by February (2017-2030)

13.3.6.3. Market Revenue and Forecast, by March (2017-2030)

13.3.6.4. Market Revenue and Forecast, by April (2017-2030)

13.3.7. Market Revenue and Forecast, by May (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by January (2017-2030)

13.3.8.2. Market Revenue and Forecast, by February (2017-2030)

13.3.8.3. Market Revenue and Forecast, by March (2017-2030)

13.3.8.4. Market Revenue and Forecast, by April (2017-2030)

13.3.9. Market Revenue and Forecast, by May (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by January (2017-2030)

13.3.10.2. Market Revenue and Forecast, by February (2017-2030)

13.3.10.3. Market Revenue and Forecast, by March (2017-2030)

13.3.10.4. Market Revenue and Forecast, by April (2017-2030)

13.3.10.5. Market Revenue and Forecast, by May (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by January (2017-2030)

13.3.11.2. Market Revenue and Forecast, by February (2017-2030)

13.3.11.3. Market Revenue and Forecast, by March (2017-2030)

13.3.11.4. Market Revenue and Forecast, by April (2017-2030)

13.3.11.5. Market Revenue and Forecast, by May (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by January (2017-2030)

13.4.2. Market Revenue and Forecast, by February (2017-2030)

13.4.3. Market Revenue and Forecast, by March (2017-2030)

13.4.4. Market Revenue and Forecast, by April (2017-2030)

13.4.5. Market Revenue and Forecast, by May (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by January (2017-2030)

13.4.6.2. Market Revenue and Forecast, by February (2017-2030)

13.4.6.3. Market Revenue and Forecast, by March (2017-2030)

13.4.6.4. Market Revenue and Forecast, by April (2017-2030)

13.4.7. Market Revenue and Forecast, by May (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by January (2017-2030)

13.4.8.2. Market Revenue and Forecast, by February (2017-2030)

13.4.8.3. Market Revenue and Forecast, by March (2017-2030)

13.4.8.4. Market Revenue and Forecast, by April (2017-2030)

13.4.9. Market Revenue and Forecast, by May (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by January (2017-2030)

13.4.10.2. Market Revenue and Forecast, by February (2017-2030)

13.4.10.3. Market Revenue and Forecast, by March (2017-2030)

13.4.10.4. Market Revenue and Forecast, by April (2017-2030)

13.4.10.5. Market Revenue and Forecast, by May (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by January (2017-2030)

13.4.11.2. Market Revenue and Forecast, by February (2017-2030)

13.4.11.3. Market Revenue and Forecast, by March (2017-2030)

13.4.11.4. Market Revenue and Forecast, by April (2017-2030)

13.4.11.5. Market Revenue and Forecast, by May (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by January (2017-2030)

13.5.2. Market Revenue and Forecast, by February (2017-2030)

13.5.3. Market Revenue and Forecast, by March (2017-2030)

13.5.4. Market Revenue and Forecast, by April (2017-2030)

13.5.5. Market Revenue and Forecast, by May (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by January (2017-2030)

13.5.6.2. Market Revenue and Forecast, by February (2017-2030)

13.5.6.3. Market Revenue and Forecast, by March (2017-2030)

13.5.6.4. Market Revenue and Forecast, by April (2017-2030)

13.5.7. Market Revenue and Forecast, by May (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by January (2017-2030)

13.5.8.2. Market Revenue and Forecast, by February (2017-2030)

13.5.8.3. Market Revenue and Forecast, by March (2017-2030)

13.5.8.4. Market Revenue and Forecast, by April (2017-2030)

13.5.8.5. Market Revenue and Forecast, by May (2017-2030)

Chapter 14. Company Profiles

14.1. Medtronic PLC

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Cyberonics

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Boston Scientific Corp.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. St. Jude Medical, Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Nevro Corp.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. MicroPort Scientific Corporation

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Kaneka Corp

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Integer Holdings Corporation

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. BALT

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Perflow Medical

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample